How many clinical trials are studying Palazestrant?

3 recruiting trials in our tracked data involve Palazestrant.

What conditions is Palazestrant being studied for?

In our tracked recruiting trials, Palazestrant is being studied in trials for Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer.

Recruiting trials

Conditions studied

US states with sites

Countries

Phase 1 2 Phase 3 1

Condition	Trials
Breast Cancer · Palazestrant for Breast Cancer	3
Metastatic Breast Cancer · Palazestrant for Metastatic Breast Cancer	3
ER Positive Breast Cancer	2
Locally Advanced Breast Cancer	2
Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)	1
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)	1
Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Fulvestrant	1
HER2 Negative Breast Carcinoma	1
HER2-negative Breast Cancer	1
Lung cancer	1
Palazestrant	1
Prostate cancer	1

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 181 locations
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations